title: Effect of loteprednol etabonate nasal spray suspension on seasonal allergic rhinitis assessed by allergen challenge in an environmental exposure unit.
abstract: BACKGROUND
  Loteprednol etabonate (LE) is a novel soft steroid that was designed to improve the benefit/risk ratio of topical corticosteroid therapy. This study assesses the clinical efficacy and safety of three different doses of LE nasal spray in seasonal allergic rhinitis (SAR).
  
  
  METHODS
  In this single-center, double-blind, placebo-controlled, parallel-group trial 165 subjects with SAR to grass pollen received daily single doses of either 100, 200, 400 microg LE nasal spray, or placebo for 14 days. The patients underwent three 4-h allergen challenges with grass pollen in an environmental exposure unit at a screening visit (baseline) and on days 7 and 14 of treatment. Standardized nasal symptom scores were obtained every 20 min. Nasal flow, nasal secretions, and FEV(1) were measured every hour during allergen challenges.
  
  
  RESULTS
  After 14 days of treatment, patients who received 400 microg LE had significantly lower total nasal symptom scores compared with those receiving placebo (P = 0.007). LE400 reduced rhinorrhea, nasal congestion, nasal itching, the amount of nasal secretions, and improved nasal flow as compared with placebo (P < 0.05). LE100 and LE200 were not significantly different from placebo. All treatments were well tolerated.
  
  
  CONCLUSIONS
  Loteprednol 400 microg once daily is superior to placebo and the only effective dose tested in improving nasal symptoms and objective parameters in patients with SAR.
authors.affiliation: Fraunhofer Institute of Toxicology and Experimental Medicine, Hannover, Germany.
authors.forename: N
authors.initials: N
authors.lastname: Krug
authors.forename: J M
authors.initials: JM
authors.lastname: Hohlfeld
authors.forename: H
authors.initials: H
authors.lastname: Geldmacher
authors.forename: M
authors.initials: M
authors.lastname: Larbig
authors.forename: R
authors.initials: R
authors.lastname: Heermann
authors.forename: N
authors.initials: N
authors.lastname: Lavallee
authors.forename: D T
authors.initials: DT
authors.lastname: Nguyen
authors.forename: U
authors.initials: U
authors.lastname: Petzold
authors.forename: R
authors.initials: R
authors.lastname: Hermann
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000336:Aerosols; D000485:Allergens / Q000276:immunology*; D000730:Androstadienes / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D018926:Anti-Allergic Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004781:Environmental Exposure; D005260:Female; D006801:Humans; D000069559:Loteprednol Etabonate; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000276:immunology* / Q000503:physiopathology; D013535:Suspensions; D016896:Treatment Outcome
chemical_list: D000336:Aerosols; D000485:Allergens; D000730:Androstadienes; D018926:Anti-Allergic Agents; D013535:Suspensions; D000069559:Loteprednol Etabonate